Healthcare & Life Sciences

TNF Inhibitor for Gastrointestinal Disease Treatment, EP3810095A1

The EPO published patent application EP3810095A1 for BT Bidco, Inc., covering a TNF inhibitor formulation for treating gastrointestinal diseases. The patent application was published under IPC classifications A61K 9/22, A61K 31/436, and A61K 48/00. The application designates all EU member states plus other EPC contracting states including CH, GB, LI, MC, NO, TR, and IS.

Hydrocortisone for Treatment of Mastitis in Non-Human Mammals, EP3829591A1

The European Patent Office published Patent Application EP3829591A1 for VIRBAC covering hydrocortisone formulations for treating mastitis in non-human mammals. The application names inventors HAVRILECK Bertrand, JASMIN Pierre, and MCGAHIE David with IPC classifications in A61K therapeutic preparations. The designated states cover EU contracting states including AT, BE, DE, ES, FR, GB, IT, NL, PL, and others.

Compounds, Compositions, Methods, and Uses for Treating Cancer and Immunological Disorders

The European Patent Office granted Patent EP3820533A2 to IL-2RX, Inc. covering novel compounds and compositions for treating cancer and immunological disorders. The patent application, filed by inventors Soares and Hurt, was published April 8, 2026 under IPC classifications A61K 47/64, A61K 47/65, A61P 35/00, and A61P 37/02. The patent is designated for all EU member states and extended territories.

Thiocycloheptyne Derivatives and Their Use

The EPO published European patent application EP3820858A1 for thiocycloheptyne derivatives and their pharmaceutical use, filed by Cristal Delivery B.V. The patent covers thiocycloheptyne compound compositions and their therapeutic applications under IPC classification A61K. The patent is validated in all designated EU contracting states including Germany, France, the United Kingdom, Italy, Spain, and 24 other jurisdictions.

LEAD Model Features, Five Legal Issues for ACOs

K&L Gates LLP published a primer on the Long Term Enhanced ACO Design (LEAD) Model, outlining its key features and five legal considerations for Accountable Care Organizations and providers evaluating participation. The article provides background on the model and discusses implications for accountable care arrangements under Medicare.

Biotech Insights - Spring 2026

Haynes Boone published its Spring 2026 biotech regulatory update covering FDA post-approval change requirements for New Drug Applications and a Federal Circuit patent eligibility ruling. The article explains that NDA changes are categorized as major (prior FDA approval required), moderate (30 days after supplement filing), or minor (annual report only), with dosage form changes typically requiring a new NDA. The piece also analyzes the Federal Circuit's decision in REGENXBIO v. Sarepta upholding patent eligibility for engineered host cells containing heterologous non-AAV sequences.

FDA Encourages Sponsors to Pursue New Testosterone Therapy Indication for Low Libido

The FDA announced it is taking an initial step to expand treatment options for men with low libido by encouraging sponsors of approved testosterone replacement therapy (TRT) products to express interest in pursuing a potential new indication for idiopathic hypogonadism. Following a preliminary review of published clinical literature and a December 2025 expert panel discussion, FDA identified data suggesting TRT may be safe and effective for certain men with low libido related to low testosterone without an identifiable cause.

Phase 1 Pomalidomide After CAR T-Cell Therapy for Relapsed or Refractory CD19+ B-Cell Leukemia or Lymphoma

The NIH National Library of Medicine registered Phase 1 clinical trial NCT07532525 to evaluate pomalidomide following CD19 CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma. The single-arm trial will assess safety and preliminary effectiveness of the combination therapy in approximately 24 participants.

Orthodontic and Articular Effects of the One-Step No-Prep Protocol

NIH's ClinicalTrials.gov registered a new observational study (NCT07533240) investigating the One-Step No-Prep protocol for treating localized tooth wear in adults. The study will evaluate orthodontic tooth movements, temporomandibular joint function, and restoration stability using digital scans, 3D imaging, and jaw-tracking. Participants will receive bonded restorations combined with orthodontic mechanics and complete questionnaires on comfort and satisfaction.

Impact of Atypical Swallowing on Periodontal Health in Adults

The NIH ClinicalTrials.gov registry has posted NCT07534306, an observational study examining the prevalence of atypical (dysfunctional) swallowing in adults with periodontitis. The study will investigate correlations between abnormal tongue thrust patterns and clinical oral manifestations including dental mobility and periodontal deterioration. Researchers will collect data through patient questionnaires and clinical evaluations to assess how incorrect lingual posture affects tooth-supporting tissues.

Chemogenetic Gene Therapy for Parkinson's Disease Using AAV Virus and Stereotactic Surgery

NIH registered a Phase 1 clinical trial (NCT07533591) evaluating a chemogenetic gene therapy called STP-001 for Parkinson's disease. The therapy uses an AAV viral vector with hM4Di chemogenetic effector delivered via stereotactic surgery to the subthalamic nucleus, combined with clozapine to modulate neuronal activity. The study aims to improve core motor symptoms in PD patients.

Real-Time MAP Forecasts, Cesarean Delivery Pilot Study

NIH's ClinicalTrials.gov registered a single-center, open-label pilot study (NCT07534774) evaluating a real-time maternal mean arterial pressure (MAP) decision-support algorithm during elective cesarean delivery under spinal anesthesia. The clinician-facing display provides 1-, 2-, and 3-minute MAP forecasts from spinal anesthesia administration until delivery or up to 20 minutes. Clinicians retain full autonomy over treatment decisions with no dosing recommendations provided. Primary outcome is prospective accuracy of short-horizon MAP forecasts; secondary outcomes assess intraoperative hypotension burden and phenylephrine exposure.

Novel Hollow Cusp Fracture Reducer Clinical Evaluation

NIH ClinicalTrials.gov registered and published results from a prospective randomized controlled trial (NCT07534904) conducted at Hanzhong Central Hospital between January 2020 and January 2023, evaluating a novel hollow cusp fracture reducer device against conventional manual reduction in 142 patients with femoral shaft and patellar fractures. The device group showed significantly reduced operative time and intraoperative fluoroscopy frequency, improved K-wire placement accuracy, and accelerated fracture healing compared to conventional techniques.

Effects of 7-Day Creatine Supplementation on Cognitive Function After High-Intensity Interval Training in Active Young Men

NIH ClinicalTrials.gov registered a new clinical trial (NCT07534293) to evaluate whether 7-day creatine monohydrate supplementation affects cognitive function after high-intensity interval training in active young men. The randomized controlled trial will enroll 20 participants across four groups receiving placebo or creatine at 0.1 or 0.3 g/KgBW/day, with or without exercise, measuring outcomes via visual reaction time and Trail Making Tests. The trial is listed as Not Yet Recruiting with an anticipated completion date of April 16, 2026.

Phase 1 CD19 CAR-γδ T Cells for Relapsed/Refractory Autoimmune Nephropathy

NIH registered a Phase 1 clinical trial (NCT07535138) evaluating CD19 CAR-γδ T cell therapy for patients with relapsed/refractory autoimmune nephropathy, including lupus nephritis, IgA nephropathy, and membranous nephropathy. The single-arm, single-center, open-label dose-escalation study will use a 3+3 design to assess safety, tolerability, recommended dose, and maximum tolerated dose over a 1-year follow-up period.

Elecoglipron and Statins PK Study Phase 1 in Healthy Participants

NIH registered a Phase 1 clinical trial (NCT07534592) to investigate pharmacokinetic interactions between elecoglipron and statins (atorvastatin and rosuvastatin) in healthy participants. The single-center study will enroll participants in two groups to assess co-administration effects. Elecoglipron is an investigational drug not yet approved by FDA.

EIT Pilot Study Tests Perfusion and Ventilation Distribution in Children

The NIH has registered a new pilot study (NCT07532811) on ClinicalTrials.gov evaluating the feasibility of assessing pulmonary perfusion in children using electrical impedance tomography (EIT) with a weight-adjusted hypertonic saline bolus. The study addresses a gap in pediatric protocols, as existing adult perfusion assessment methods using 10 mL of 7.5-10% NaCl are unsuitable for small children. The single-center study targets children with acute respiratory failure.

RESMED Vent System Patient Interface Patent Granted

USPTO granted patent US12594397B2 to ResMed Pty Ltd on April 7, 2026, covering a vent system for patient interface used in CPAP/BiPAP mask ventilation. The patent describes a vent housing with an inlet, outlet, exhaust gas orifice, and an elastically deformable moveable membrane that responds to pressure differences to regulate exhaust gas flow. The patent contains 46 claims and has a filing date of February 26, 2020.

ConvaTec Limited Catheter Medical Device Patent B2

The USPTO granted US Patent 12594399B2 to ConvaTec Limited on April 7, 2026, covering a catheter medical device. The patent discloses a tubular body portion with a proximal and distal end and a cuff mounted to the distal end portion. Assignee: ConvaTec Limited. Inventors: Mingliang Lawrence Tsai and Pavel Zeliankevich. The patent contains 20 claims under CPC classification A61M.

Guide Wire with Pseudoelastic Core Shaft and Auxiliary Wire - US12594404B2

USPTO granted patent US12594404B2 to ASAHI INTECC CO., LTD. for a guide wire featuring a core shaft with a pseudoelastic distal end portion and an auxiliary wire arranged parallel to the distal end portion, having high flexibility and breaking strength. The patent, assigned 4 claims, covers inventions by Keisuke Ushida and Masahiro Kashiwai.

Serration Balloon Medical Device Patent Granted to Cagent Vascular

USPTO granted patent US12594406B2 to Cagent Vascular, Inc. for a serration balloon medical device. The invention comprises longitudinally extending members with periodic raised wedges attached to an angioplasty balloon via fiber coating or polymer matrix bonding. The patent includes 22 claims and was filed on June 1, 2023.

Mayor Bowser Announces 21st Emancipation Day Celebration, New Location

Mayor Muriel Bowser announces the 21st annual DC Emancipation Day celebration on Sunday, April 19, 2026. The event moves to a new location at 13th Street and Pennsylvania Avenue NW. The free day-long celebration includes a festival, parade, and star-studded concert featuring T.I., Mýa, and Tye Tribbett. DC Emancipation Day commemorates the 1862 signing of the DC Compensated Emancipation Act, which freed more than 3,100 enslaved people.

Fisher & Paykel Healthcare, US Patent B2, 7th Apr

Fisher & Paykel Healthcare, US Patent B2, 7th Apr

Movable Tip Bougie Device

USPTO granted patent US12594392B2 to Imam Abdulrahman Bin Faisal University for a movable bougie tip device. The device features a tip section with holder and recoiled wire, and a bougie section with slide button for adjusting tip angle between 30° and 90°. The device prevents kinking via a recoiled wire mechanism and uses silk thread threading through an opening in the tip. Application 17994768 was filed November 28, 2022 with 17 claims.

Sound Masking System for Respiratory Device, ResMed

USPTO granted Patent US12594398B2 to ResMed Sensor Technologies Limited for a sound masking system that detects air leaks from respiratory masks and emits masking sounds. The system includes a microphone, speaker, and control system to analyze audio data and determine if mask leakage noise is occurring, then triggers sound emission to mask the noise. The patent contains 20 claims and was filed on October 4, 2022.

Delivery System with Torqueable Catheter Shaft

USPTO granted Patent US12594400B2 to Medtronic, Inc. on April 7, 2026. The patent covers a delivery system with a torqueable catheter shaft design featuring multiple polymer layers with varying stiffness, tubular braid components, and hypotube configurations for improved torque transmission. The patent contains 20 claims.

Catheter with Serially Connected Sensing Structures and Methods of Calibration and Detection

USPTO granted Patent US12594402B2 to Biosense Webster (Israel) Ltd. covering catheters with serially connected position and pressure sensing coils designed to reduce lead breakage and failure. The patent includes methods for calibration, position/pressure sensing, and detecting magnetic field interference between catheters or metal objects using dual sensor signals as an error-check mechanism.

Bard Access Introducer Assembly Patent, 17 Claims

USPTO granted Patent US12594403B2 to Bard Access Systems, Inc. on April 7, 2026. The patent covers introducer components, assemblies, and methods including an access guidewire loaded in a needle assembly with a valve mechanism. The patent contains 17 claims and has a filing date of August 24, 2022.

US12594407B2 - Multi-Needle Preparation Delivery Device Patent Granted to Beijing Boe Technology

The USPTO granted patent US12594407B2 to Beijing Boe Technology Development Co., Ltd. on April 7, 2026, covering a preparation delivery assembly and device with multiple needles of varying lengths. The patent includes 15 claims and is classified under A61M medical device categories. The invention features a dual-substrate design with channels and chambers for controlled delivery of preparations through needles of different lengths.

Surgical Instrument Ports for Wound Retractors (US12594408B2)

The USPTO granted patent US12594408B2 to Intuitive Surgical Operations, Inc. for surgical instrument ports configured for use with wound retractors. The patent covers ports with channels to receive surgical instrument cannulas and lateral walls for engagement with wound retractor end portions. The patent has 22 claims and inventors include Brian M. Crews, Sam Crews, Craig R. Gerbi, Michael Hurst, and Sumona Adhya.

US12594409B2 - Surgical Port Sleeve with Reversibly Radially Expandable Flanges

USPTO granted Patent US12594409B2 to University Hospitals Cleveland Medical Center on April 7, 2026, covering a sleeve for retention of a surgical port with reversibly radially expandable flanges. The patent claims a first sleeve portion, a second reversibly slidable sleeve portion, a plurality of radially expandable flanges, and a reversible locking mechanism. The patent contains 13 claims and was filed on April 3, 2024 under Application No. 18853697.

ICU Medical Patent, Antimicrobial Delivery Device for Medical Device Connections

USPTO granted patent US12594410B2 to ICU Medical, Inc. for a device that delivers antimicrobial composition into medical device connections. The device comprises a male connector with a recess containing chlorhexidine acetate at the distal tip to prevent infection and microbial ingress. The patent includes 20 claims.

US12594411B2 - Apparatus and Method for Joining Metal Sleeve onto Tube for Catheters

USPTO granted patent US12594411B2 to Best Medical International, Inc. covering an apparatus and process for joining metal or ceramic sleeves onto flexible tubular members for catheter applications. The invention uses friction-based material joining with rotational heating to create integral seals. The patent protects the assignee's manufacturing process for medical catheters and flexi needles.

Flush Syringe with Multiple Scrubbing Devices - US12594412B2

The USPTO granted patent US12594412B2 to Becton, Dickinson and Company for an integrated flush syringe assembly with two disinfection units containing absorbent materials, disinfectants, and peelable seals, using threaded luer lock connections and snap-fit interlocks. The patent contains 19 claims covering dual-cup assemblies with antimicrobial agents for disinfecting medical connector access ports. Medical device manufacturers and competitors should review the granted claims to assess IP scope and freedom-to-operate implications for similar fluid delivery and disinfection products.

Impact of Eating Disorders Study

NIH registered observational clinical trial NCT07534059 titled 'Impact of Eating Disorders Study' on ClinicalTrials.gov. The study examines eating disorders including anorexia nervosa and bulimia nervosa in adolescent populations, with estimated prevalence data for anorexia nervosa at 2-3% among young adults and a 5-10% 10-year mortality rate. This is a registry entry providing study information and does not create compliance obligations.

GT307 TIL Injection Clinical Trial for Metastatic Solid Tumors

NIH ClinicalTrials.gov registered a new single-center, single-arm, open-label clinical study (NCT07534813) evaluating GT307, an autologous tumor-infiltrating lymphocyte (TIL) injection, in patients with advanced solid tumors. The Phase I/II trial will assess safety, tolerability, pharmacokinetics, efficacy, and optimal dosing. The study is registered with an anticipated start date of April 16, 2026.

Post-Debonding Finishing in Orthodontics - Observational Study NCT07534423

NIH registered observational study NCT07534423 investigating clinical approaches to orthodontic debonding and post-debonding finishing, focusing on enamel preservation. The study conducted an observational epidemiological survey among dental professionals to assess techniques, instruments, and complications. Results highlight variability in clinical protocols, with mechanical methods being most widely adopted, and emphasize minimally invasive strategies to reduce enamel damage and improve patient outcomes.

Animal-Shaped Magic Mirrors Reduce Child Vaccination Pain

NIH registered observational study NCT07535151 on April 16, 2026, examining the effect of animal-shaped magic mirrors on pain in children aged 1-4 years during vaccination and maternal anxiety. The single-center study aims to evaluate non-pharmacological interventions for reducing procedural pain in pediatric populations. Results may inform clinical practices for managing vaccination-related distress in young children.

Rescue Treatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing

NIH's ClinicalTrials.gov has registered a new Phase 4 clinical trial (NCT07533422) evaluating fecal-based antimicrobial resistance gene testing to guide personalized Helicobacter pylori rescue therapy. The study will enroll patients who have failed initial treatment and compare personalized treatment based on fecal resistance profiles against conventional quadruple therapy, measuring eradication rates and safety outcomes.

Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled Study

NIH registered a clinical trial (NCT07533526) on ClinicalTrials.gov comparing instrument-assisted constant-speed injection versus manual injection for subcutaneous administration of pertuzumab and trastuzumab in breast cancer patients. The randomized, self-controlled study plans to enroll 40 female patients, with each receiving both injection methods across two treatment cycles. Pain intensity will be measured using the Numerical Rating Scale immediately after injection.

Characterization of Pulp Inflammation: Observational Study Using Biological Samples

NIH registered ClinicalTrials.gov study NCT07533396, an observational investigation of pulpal inflammation using biological samples collected during routine dental care. The study aims to validate a new diagnostic classification (Endolight) for guiding vital pulp therapy indications and to identify molecular and protein biomarkers associated with inflammatory severity. The trial enrolls patients undergoing routine dental procedures and requires collection of biological samples for analysis.

OMT vs Exercise in TMD Clinical Trial

NIH ClinicalTrials.gov registered a randomized clinical trial (NCT07534540) comparing osteopathic manipulative treatment (OMT) versus a structured home-based exercise program in adults diagnosed with myogenic temporomandibular disorders (TMD). The trial will assess pain intensity, functional outcomes, postural stability, and quality of life across intervention groups. Enrollment status and specific trial sites are not detailed in the registry record.

PancreasPlus App Monitors Pancreatic Cancer Patients

NIH ClinicalTrials.gov registered study NCT07532590 evaluating the PancreasPlus mobile app for pancreatic cancer patients. The single-arm feasibility study will assess patient engagement, questionnaire completion rates, perceived service quality, and anxiety reduction through use of the app for remote symptom monitoring and caregiver support. The study anticipates enrolling patients over an undefined period with a primary completion date of April 16, 2026.

Observational Study Comparing Leadless Pacemakers and Left Bundle Branch Area Pacing

NIH registered clinical trial NCT07534917, an observational acute study comparing leadless right ventricular pacemakers and temporary left bundle branch area pacing on cardiac function and tricuspid valve. Both procedures conducted in one sitting under general anesthesia. Participants referred for routine pacemaker implantation may enroll. The study aims to guide pacemaker type selection for patients at risk of valve or heart dysfunction.

Philips Ingenia and Achieva MRI Systems - MRE Liver Stiffness Measurement Recall

Health Canada has issued a Type I recall for Philips Ingenia and Achieva MRI Systems following identification of two software issues affecting diagnostic accuracy. The primary issue involves MRE (Magnetic Resonance Elastography) stiffness measurements where default scan protocol voxel size settings are too small, potentially producing inaccurate (lower) liver stiffness values. A secondary issue affects Philips Vue Motion v12.2.0-v12.2.8.500 where mis-ordered image frames during dynamic cine runs may display out of sequence. Affected products include multiple Ingenia and Achieva 3.0T models with specific lot numbers.

Effect of Different Volumes of Erector Spinae Plane Block on Postoperative Opioid Consumption After Total Abdominal Hysterectomy

NIH's ClinicalTrials.gov has registered a new observational study (NCT07533760) investigating the effects of different volumes of ultrasound-guided erector spinae plane block on postoperative pain and opioid consumption in patients undergoing total abdominal hysterectomy. The study will evaluate whether varying local anesthetic volume reduces morphine requirements and improves pain scores during the first 24 hours after surgery. No compliance obligations or regulatory actions are associated with this trial registration.

Blood Flow Restriction Parameters and Lower Limb Function in Older Adults With Dynapenia

NIH registered clinical trial NCT07534150, a two-phase study examining limb occlusion pressure (LOP) measurements and muscle electrophysiology in older adults with dynapenia. Year one collects baseline LOP data and influencing factors; year two uses high-density surface electromyography to analyze motor unit recruitment under varying BFR pressures. No regulatory obligations imposed.

Placebo-Induced Hypoalgesia During TENS Application in Low Back Pain

NIH's ClinicalTrials.gov registered a randomized controlled trial (NCT07535047) evaluating transcutaneous electrical nerve stimulation (TENS) combined with video-based education for acute low back pain. The study will enroll participants divided into control group (standard physical therapy with TENS and exercises) and experimental group (standard therapy plus video-based TENS educational explanation). The primary outcome measures are feasibility of conducting the full RCT, including recruitment, compliance, and adverse events. Secondary outcomes include pressure pain threshold, pain intensity, functional mobility, patient satisfaction, and quality of life.

Phase 4 Elagolix vs OCPs Endometriosis Pain Clinical Trial NCT07532876

NIH's ClinicalTrials.gov has registered a Phase 4 clinical trial (NCT07532876) comparing Elagolix to oral contraceptive pills (OCPs) for reducing endometriosis-associated pelvic pain. The randomized, open-label study aims to provide direct evidence on relative effectiveness and safety to help physicians make more tailored treatment decisions for patients with diagnosed endometriosis. Elagolix is an oral GnRH antagonist intervention.

Novel Infant Formula Randomized Trial, Ages 12-18 Months

NIH has registered a new randomized controlled clinical trial on ClinicalTrials.gov (NCT07534735) to evaluate the effects of investigational infant formulas on growth, gut health, immune function, and sleep in healthy infants aged 12-18 months. The three-arm study will compare two investigational formulas against a control.